摘要
目的探讨新辅助化疗治疗三阴性乳腺癌的疗效及预后情况。方法选择102例乳腺癌患者,其中经病理组织学确诊的三阴性乳腺癌患者42例为观察组,非三阴性乳腺癌患者60例为对照组。观察并对比分析两组患者新辅助化疗的疗效及预后情况。结果应用紫杉醇联合顺铂方案治疗42例三阴性乳腺癌患者,完全缓解率16.67%,总有效率64.29%,均明显高于对照组的5.00%、51.67%,两组比较差异有统计学意义(P<0.05),但观察组复发转移率和无瘤生存率高/低于对照组(P<0.05),化疗后不良反应情况主要为中性粒细胞、血小板、血红蛋白减少及消化系统不良反应,均能耐受,不影响化疗完成。结论紫杉醇联合顺铂用于三阴性乳腺癌新辅助化疗有较高的完全缓解率。
Objective To explore the curative effect and prognosis of neoadjuvant chemotherapy in treatment of three negative breast cancer. Methods A total of 102 cases of patients with breast cancer were selected, and 42 cases of TNBC patients who were confirmed by pathological histology were selected as the observation group, while 60 cases of the no-three negative breast cancer patients were selected as the control group. Curative effect and prognosis of neoadjuvant chemotherapy in two group patients were observed and compared. Results The complete response rate of 42 cases of TNBC patients who were treated with paclitaxel plus cisplatin regimen was 16.67% and the total effective rate was 64.29%, all significantly higher than that of the control group （5.00%, 51.67%）, had statistical significance between the two groups （P〈0.05）, but the recurrence metastasis rate and disease-free survival rate of obervation group were higher/lower than control group （P〈0.05）, adverse reaction after chemotherapy of main neutrophil and platelet, hemoglobin and the digestive system adverse reactions were tolerated in two groups, and the chemotherapy was not affected, the adverse reaction conditions were similar in the two groups. Conclusion The complete response rate of paclitaxel plus cisplatin neoadjuvant chemotherapy for three negative breast cancer is higher.
出处
《中国现代医生》
2014年第16期137-139,142,共4页
China Modern Doctor
关键词
乳腺肿瘤
三阴性乳腺癌
新辅助化疗
预后
Breast tumor
Three negative breast cancer（TNBC）
Neoadjuvant chemotherapy
Prognosis
